Trials / Completed
CompletedNCT00488787
Safety and Efficacy of Intranasal Ketamine for the Treatment of Postoperative Dental Pain
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of 10 mg, 30 mg, and 50 mg of Transnasal Ketamine Hydrochloride (PMI-100) for the Treatment of Postoperative Dental Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Javelin Pharmaceuticals · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
Once patients' postoperative pain intensity reaches a moderate-to-severe level, they are randomized to receive intranasal ketamine or placebo. Patients remain in the study unit for 3 hours post administration and assess pain intensity and pain relief throughout the 3 hour postoperative period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intranasal ketamine | low dose |
| DRUG | intranasal ketamine | medium dose |
| DRUG | intranasal ketamine | high dose |
| DRUG | placebo | placebo |
Timeline
- Start date
- 2001-03-01
- Primary completion
- 2001-04-01
- Completion
- 2001-04-01
- First posted
- 2007-06-20
- Last updated
- 2008-02-07
Source: ClinicalTrials.gov record NCT00488787. Inclusion in this directory is not an endorsement.